$LBPH News
Last published 7mo ago
- 7mo agoLBPHARNAKYTHSensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual ReportBusiness WireGJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month
- 1y agoLBPHARNAKYTHAGN+1Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent DirectorBusiness WireRegulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today
- 1y agoLBPHLongboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)Business WireDEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadly Initial sites activated with additional sites expected to be activated in the coming weeks Longboard Pharmaceuticals, Inc.
- 2y agoLBPHLongboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesBusiness WirePositive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years Recently initiated Phase 3 global
- 2y agoPRMWFBMSEVRILBPHKuehn Law Encourages PRMW, FBMS, EVRI, and LBPH Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoLBPHLundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience PipelineBusiness WireThe proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic
- 2y agoLBPHLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 2y agoLBPHLongboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet SyndromeBusiness WireFirst sites activated with a number of additional rapid-start sites being activated in the coming weeks Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing
- 2y agoLBPHLongboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet SyndromeBusiness WireU.S. Food and Drug Administration (FDA) has granted Orphan Drug designation and Rare Pediatric Disease designation for bexicaserin for the treatment of Dravet syndrome Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a
- 2y agoLBPHLongboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)Business WireBexicaserin achieved an overall median seizure reduction of 57.7% in countable motor seizures over an approximate 9-month treatment period Favorable safety and tolerability results continue to be observed Data to
- 2y agoLBPHLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 2y agoLBPHLongboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in SeptemberBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its leadership
- 2y agoLBPHLongboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy CongressBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data at the
- 2y agoLBPHLongboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor
- 2y agoLBPHLongboard Pharmaceuticals, Inc. (LBPH) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLBPHLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 2y agoLBPHLongboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesBusiness WireBexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or
- 2y agoLBPHLongboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1Business WireConference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm
- 2y agoLBPHLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 2y agoLBPHLongboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)Business WireU.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) Longboard
- 2y agoLBPHLongboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)Business WireBexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure
- 2y agoLBPHLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 2y agoLBPHLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 2y agoLBPHLongboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesBusiness WireBexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) were reported in Q1 2024 Presented late-breaking data for bexicaserin from
- 2y agoLBPHLongboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15Business WirePACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annual Meeting Data will be featured in an encore presentation at the Seventeenth Eilat
- 2y agoLBPHLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 2y agoLBPHLongboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate UpdatesBusiness WireBexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) was reported in January Announcing an update to the primary efficacy
- 2y agoLBPHLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 2y agoLBPHLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 2y agoLBPHLongboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in FebruaryBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior
- 2y agoLBPHLongboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously
- 2y agoLBPHLongboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of an upsized
- 2y agoLBPHLongboard Pharmaceuticals Announces Commencement of Public Offering of Common StockBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an
- 2y agoLBPHLongboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)Business WireBexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in Dravet Syndrome
- 2y agoLBPHLongboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)Business Wire• Conference call and webcast to be held tomorrow, January 2, at 8:30am ET (5:30am PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel,
- 2y agoLBPHLongboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy VolunteersBusiness WireInitiated Single-Ascending Dose (SAD) Phase 1 clinical study evaluating LP659 Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative
- 2y agoLBPHLongboard Pharmaceuticals' Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy CommunityBusiness WirePresenting new posters including favorable drug interaction, pharmacokinetic and pharmacodynamic data further highlighting the potential of LP352 to be a best-in-class therapy for a broad range of Developmental and
- 3y agoLBPHLongboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
- 3y agoLBPHLongboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsBusiness WireLP352 Phase 1b/2a PACIFIC Study enrollment completed in August 2023 with topline data on track for January 2024 LP659 first-in-human Phase 1 single-ascending dose (SAD) study initiation expected Q4 2023, with
- 3y agoLBPHLongboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in NovemberBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior
- 3y agoLBPHLongboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the speakers for its upcoming
- 3y agoLBPHLongboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor
- 3y agoLBPHLongboard Pharmaceuticals to Participate in Three Upcoming Investor ConferencesBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior
- 3y agoLBPHLongboard Pharmaceuticals to Present Data at Upcoming Medical MeetingsBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and
- 3y agoLBPHLongboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic EncephalopathiesBusiness WireEnrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study Participants have a broad range of DEEs including Lennox-Gastaut syndrome, Dravet syndrome, SCN2A-related
- 3y agoLBPHLongboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsBusiness WireLP352 Phase 1b/2a PACIFIC Study enrollment completion expected this summer with topline data expected around year-end 2023 Ended second quarter 2023 with $63.0 million in cash, cash equivalents and investments; cash
- 3y agoLBPHLongboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023Business WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team
- 3y agoLBPHLongboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial ResultsBusiness WireLP352 Phase 1b/2a PACIFIC Study topline data expected in fourth quarter 2023 LP659 IND submitted to FDA after incorporating input from a pre-IND meeting; Phase 1 initiation of first in-human clinical study on track
- 3y agoLBPHLongboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare ConferenceBusiness WireLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard's
- 3y agoLBPHLongboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate InitiativesBusiness WireLP352 Phase 1b/2a PACIFIC Study remains on track to complete enrollment in the first half of 2023, with topline data expected in the second half of 2023 LP659 Phase 1 initiation of first in-human clinical study on